Please provide your email address to receive an email when new articles are posted on . WASHINGTON — The Staar Surgical Evo ICL can correct a wide range of myopia in those with thin or irregular ...
$5 million represents STAAR's highest quarterly ICL sales in U.S. since it obtained FDA approval for EVO ICL in March 2022. Analyst says achieving STAAR Surgical's revenue target for 2026 seems ...
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, ...
“EVO ICL is the next logical step in refractive innovation. While adoption of any new technology takes time, EVO ICL’s adoption rate has been steadily rising since launch – achieving market leadership ...
(RTTNews) - STAAR Surgical Company (STAA) Tuesday announced partnership with ophthalmology group, SharpeVision to provide EVO ICL lenses to all qualified patients in SharpeVision clinics. STAAR ...
The center is equipped with microscopes and wet lab situations Staar Surgical Co. last month unveiled the new location of its company-owned ophthalmology training center. The eye lens maker moved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results